ClinicalTrials.gg
CompletedNCT01403350Updated Jul 15, 2022

Cluster Randomised Trial of Malaria RDTs Used by CHWs in Afghanistan

A Phase 4 interventional study of Malaria Rapid Diagnostic test in Malaria, Fever and Acute Febrile Illness, sponsored by London School of Hygiene and Tropical Medicine. Completed at 3 sites in Afghanistan. Per ClinicalTrials.gov, last updated 2022-07-15.

Sponsored by London School of Hygiene and Tropical Medicine · Phase 4, Interventional, and Diagnostic

Phase
Phase 4
Study type
Interventional
Enrollment
2,421
Allocation
Randomized
Sex
All
01

Study summary

Malaria is a common, but decreasing, cause of fever in endemic areas. The use of rapid diagnostic tests could improve treatment of malaria at the local community level. Deployment of these tests is, however, a considerable cost. The aim of the study is to evaluate their effect on improving treatment of fever when used by Community Health Workers in Afghanistan. In phase I of the study, the hypothesis is that an RDT diagnosis deployed with standard training and support will improve the accuracy of treatment applied to fever by community health workers when compared to a diagnosis that is based on symptoms alone. In Phase II of the study, the hypothesis is that the accuracy of treatment can be improved by additional training and supportive interventions given to community health workers compared to those who have only had standard training.

Read the detailed description

This is a cluster randomised trial conducted in 22 clinics (clusters) in two provinces of Afghanistan. Clinics in Afghanistan have a number of community health workers (CHWs) who are residents of villages near to the clinic. The clinic provides them with their supplies of drugs and other items (e.g. family planning interventions) and the CHW provides a range of services in the community including treatment of acute episodes of fever. Currently, the CHW has no way of diagnosing malaria, except based on the presenting signs and symptoms of the patient. With this method is it likely that many patients who do not have malaria, but have a fever, are treated with antimalarial drugs and some patients with malaria are likely not to be treated with an antimalarial drug.

The use of Rapid Diagnostic Tests (RDT) for malaria could potentially provide the CHW with an easy and safe way of diagnosing malaria based on the presence or absence of parasites in the blood. However, use of tests is not straightforward. They need to be applied correctly, following a strict protocol, to be accurate. There is now much interest in widespread deployment of these tools which are recommended by the World Health Organisation for all fever patients in malaria endemic areas. However, evidence for their effectiveness when used by CHWs is patchy and there are no randomised trials that have been conducted in Asia. Since they represent a considerable cost, examination of their effectiveness is required.

In Asia (unlike most of Africa), malaria is caused by two species - Plasmodium vivax accounts for the majority of cases and P. falciparum for the minority. Treatments differ between the species because of differing drug resistance patterns. Therefore accurate diagnosis is important for providing accurate treatment for the different types of malaria and also for treatment of cases of fever who do not have malaria with alternative treatments. In areas where health services are restricted by short opening hours, insecurity, or inaccessibility due to distance or terrain, the CHW should be able to use RDTs and apply the correct treatment for both a positive and a negative test at the village level.

This study will randomise 22 clinics (and their constituent CHWs) to receive either an RDT for use by the CHW in diagnosing malaria in patients with fever, or no intervention (the current situation) where CHWs base their treatment decisions on symptoms alone (i.e. there is no parasite based diagnosis). The RDT group will be given the standard national training for use of RDTs and management of malaria and the standard supplies. The non-RDT arm will have training on management of malaria and a short introduction to RDTs. The study will measure the accuracy of treatment applied by the CHW in the RDT vs. the non-RDT arms, and examine the accuracy of the RDT itself when it is applied in the field under operational conditions. The accuracy will be measured by collecting filter paper blood spots from the patients which will be tested by PCR for malaria. A variety of comparisons will be made between the two groups, but the main aim is to measure and difference in accurate treatment of the patients according to the reference (PCR) diagnosis.

In phase II of the study the non-RDT arm will be discontinued and the clinics will be re-randomised to different interventions. One group of clinics will have the standard RDT roll out continued, as previously, and the second group will get additional training and a range of supportive interventions to assist in their practice. The second phase will use the same methods of assessing the study outcomes. The aim of the second phase is to see whether additional training (and cost) results in improved practice by CHWs.

02

Conditions studied

  • Malaria
  • Fever
  • Acute Febrile Illness
  • Pneumonia

Keywords

  • Malaria
  • Fever
  • Acute febrile illness
  • Pneumonia
  • Community health worker
  • Rapid diagnostic test
03

In context

Malaria

1,184 studies on the registry are indexed under Malaria; 79 are open to participants now.

This study's enrollment of 2,421 is above the median of 252 across 937 interventional studies indexed under Malaria.

Browse Malaria studies →

Lead sponsor

London School of Hygiene and Tropical Medicine is the lead sponsor of 298 studies on the registry; 15 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Any patient where the CHW* or clinician considers malaria in the diagnosis - either prescribing an antimalarial or would request a malaria test if available or referring for diagnosis of malaria elsewhere.

    * *any community health worker who consults with patients and prescribes treatment, and is administratively attached to one of the study clinics.

  • Patient, or parent/guardian, gives to the study.

Exclusion criteria

Exclusion Criteria:

  • Patients with a diagnostic result from another facility.
  • Patients referred on for diagnosis in the private sector.
  • Patients who have signs of severe or complicated disease and are referred prior to giving any diagnosis using the interventions.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 4
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
2,421 participants (actual)

Study arms

  • No intervention
    Current Practice

    Study Phase I: No RDT or other parasite based diagnosis; Study Phase II: RDT used under the standard programme of training and support

  • Active comparator
    Intervention Arm

    Study Phase I: RDT used under the standard programme of training and support; Study Phase II: RDTs deployed with additional programme components including improved training and supportive interventions

    Device: Malaria Rapid Diagnostic test

Interventions

  • DeviceMalaria Rapid Diagnostic test

    Study Phase I: RDT used under the standard programme of training and support; Study Phase II: RDTs deployed with additional programme components including improved training and supportive interventions

    Also known as: RDT: CareStart Pf/Pan Rapid Diagnostic Test (national standard RDT)

06

What researchers measure

Primary outcomes

  1. Proportion of cases correctly treated

    Correctly treated defined as: Those with PCR positive blood sample given an appropriate antimalarial; Those with PCR negative blood sample not given any antimalarial

    Time frame: Outcomes measured during consultation - approximately 30-40 minutes

Secondary outcomes

  1. Proportion of falciparum patients treated with artesunate combination therapy

    Measured against the PCR result from the blood sample

    Time frame: Outcomes measured during consultation - approximately 30-40 minutes

  2. Accuracy of the RDT

    Sensitivity and specificity measured against the PCR blood sample

    Time frame: Outcomes measured during consultation - approximately 30-40 minutes

  3. Accuracy of treatment given by the CHW in response to the RDT result

    Proportion of patients with a positive RDT not given and appropriate antimalarial Proportion of patient with a negative RDT who are given any antimalarial

    Time frame: Outcomes measured during consultation - approximately 30-40 minutes

  4. Cost effectiveness of the intervention(s)

    Comparative cost-effectiveness between the arms

    Time frame: Outcomes measured during consultation - approximately 30-40 minutes

07

Study locations

3 sites
  • HealthNet TPO
    Jalalabad, Nangahar, Afghanistan
  • Health Protection and Research Organisation
    Kabul, 0000, Afghanistan
  • Merlin
    Kunduz, Afghanistan
08

References and documents

Publications

  • Leslie T, Rowland M, Mikhail A, Cundill B, Willey B, Alokozai A, Mayan I, Hasanzai A, Baktash SH, Mohammed N, Wood M, Rahimi HU, Laurent B, Buhler C, Whitty CJM. Use of malaria rapid diagnostic tests by community health workers in Afghanistan: cluster randomised trial. BMC Med. 2017 Jul 7;15(1):124. doi: 10.1186/s12916-017-0891-8. PubMed 28683750 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2012, a primary completion of Aug 2012 and a completion of Aug 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 25, 2011
First posted
Jul 27, 2011
Start
Feb 2012
Primary completionActual
Aug 2012
CompletionActual
Aug 2012
Last update
Jul 15, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 15, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01403350
Collaborators
Health Protection and Research Organisation, HealthNet TPO, Medical Emergency Relief International
Responsible party
Sponsor
First posted
Jul 27, 2011
Start date
Feb 2012
Primary completion
Aug 2012
Completion
Aug 2012
Last update
Jul 15, 2022

Study contacts

Toby Leslie, PhD
principal investigator · London School of Hygiene and Tropical Medicine

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion